Now through Paytm Money, Retail Investors will be able to easily apply to buy shares in Initial Public Offers (IPOs) of various companies and can invest in these companies. Paytm said the move is aimed at providing retail investors with a full investment opportunity so that they can capitalize on the opportunity to make money and easily apply for IPOs of fast growing companies. The company said that the application process for investing in IPOs has been made completely digital and easy. This will enable investors to apply to buy shares. Paytm Money said, new features have been added to the app’s interface to improve the user experience. The company aims to achieve 8 to 10% share in the application market in the first year.
Also Check: Budget-Friendly Home Improvement Ideas
Customers will get these facilities
All retail investors will be able to apply for all IPOs immediately through the UPI ID linked to the bank account on Paytm Money. The company will provide an interface on the Paytm Money app. Through this, the investor will be able to change the bidding by going to the IPO window. Also, you will be able to cancel your application and can apply to buy shares again if needed. Paytm Money CEO Varun Sridhar said, the Indian startup ecosystem is continuously entering the capital market. Now more and more companies want to raise money from investors through public listings. Along with this, investors also now want to diversify their portfolios. This is a big opportunity for all of us. He said, in the future, we are also going to bring facilities like IPO funding, derivatives trading, margin finance.
Companies raised more than Rs 25,000 crore
Let us tell you that so far this year 25 companies have launched their IPO and raised more than Rs 25,000 crore. Among them, Root Mobile has been the best performer which has given more than 40% returns to investors after listing. The company’s stock is trading 175% above its issue price. At the same time, the second number is the IPO of Happiest Minds, which is trading 90% above its issue price. It is followed by Rossari BioTech and Gland Pharma. Most IPOs have been oversubscribed this year and they have been listed at a premium in the stock market.